Business Context and Reporting Period
Company: Inventiva S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: April 22, 2026
Context: This filing serves to incorporate by reference a press release issued on April 22, 2026 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values are reported for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The document solely references the issuance of a press release without summarizing its content.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the text of this Form 6-K. These details are contained within the attached press release (Exhibit 99.1), which is not included in the input data.
Investor Verification Checklist
- Review the full text of the press release dated April 22, 2026 (Exhibit 99.1) to understand the specific corporate event or announcement.
- Verify the impact of the announcement on the company's clinical pipeline or strategic partnerships, as Inventiva S.A. is a biopharmaceutical entity.
- Check subsequent filings for any financial implications resulting from the event described in the press release.